




The Report Committee for Karen Melissa Ayala
Certifies that this is the approved version of the following report:







Role of the SLP in Management of Huntington’s Disease: 
A Literature Review
by
Karen Melissa Ayala, B.S.C.S.D
Report
Presented to the Faculty of the Graduate School of 
The University of Texas at Austin
in Partial Fulfillment 
of the Requirements
for the Degree of 
Master of Arts
The University of Texas at Austin
May 2017  
 Dedication
In loving memory of my brother, Ramon Miranda. You have taught me the world.
Acknowledgements
My  sincerest  gratitude  to  Dr.  Maya  Henry  and  Cydney  Medford  for  your 
unwavering support and guidance. Your passion is contagious.
 v
Abstract
Role of the SLP in Management of Huntington’s Disease: 
A Literature Review
Karen Melissa Ayala, M.A.
The University of Texas at Austin, 2017
Supervisor:  Maya Henry
Huntington’s disease (HD) is a devastating, autosomal-dominantly inherited and 
progressive motor system disease that currently is estimated to affect more than 30,000 
people  in  the  United  States  (National  Institute  of  Neurological  Disorders  and  Stroke 
[NINDS],  2017).  Unfortunately,  there  is  no  cure  for  this  disease  and  prognosis  is 
generally  poor,  with  death  occurring  at  around  15-20  years  post-diagnosis  (NINDS, 
2017). Given HD’s distinct effect on motor function, most of the literature has centered 
around pharmacological treatment for movement. As a result of the disease’s progressive 
nature, cognition, and swallowing are likely to become impaired over the course of the 
disease; however, the effects of the disease on these systems have been studied to a lesser 
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extent.  Consequently,  evidence  to  support  the  efficacy  of  rehabilitative  therapies  for 
management of HD symptoms is lacking. Not only is this gap in the literature concerning, 
as  HD  carriers  could  potentially  be  missing  out  on  therapies  that  may  prove  to  be 
beneficial, but it also hinders therapists’ use of evidence-based practice for management 
of the disease. This paper examines available research regarding the management of HD 
from a  communication  sciences  and  disorders  (CSD)  perspective  for  use  by  clinical 
speech-language  pathologists  (SLPs).  Specifically,  this  literature  review  examines 
evidence-based  research  regarding  the  diagnosis,  assessment,  and  management  of 
disorders  of  speech,  language,  cognition,  and swallowing,  with the goal  of  providing 
insight into the SLP’s role in the management of HD. 
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Chapter 1:  Huntington’s Disease
Huntington’s disease is a progressive neurodegenerative and terminal illness that 
is  characterized  by  distinctive,  involuntary,  and  erratic  movements  known  as  chorea 
(Gudesblatt  &  Tarsy,  2011).  Huntington’s  chorea  was  first  made  well  known  to  the 
general public in 1872 following a lecture by George Huntington, in which he described 
the  motor  disturbances  resultant  from the  disease  (Roos,  2010).  It  was  not  until  the 
1980’s, when scientists became fully aware of other non-motor symptoms associated with 
the disease, that its name was changed to Huntington’s disease (Roos, 2010). Considered 
a  rare  disease,  it  is  estimated  that  HD  affects  5-10  per  100,000  individuals  in  the 
Caucasian  population  and  more  than  30,000  people  in  the  U.S.  alone  (Roos,  2010; 
NINDS,  2017).  The  average  age  of  onset  is  around  30  to  50  years  of  age  with  an 
approximated  lifespan  of  15-20  years  post-diagnosis  (NINDS,  2017).  HD  is  an 
autosomal-dominantly inherited disease, meaning that it can be passed down to both male 
and female children with a 50% chance of inheritance, requiring only one parental carrier 
of the chromosomal mutation (Roos, 2010). The affected gene, also known as the HD 
gene, is responsible for production of the Huntingtin protein; however, the purpose of this 
protein is currently unknown (Gudesblatt & Tarsy, 2011). The mutation occurs on the 
fourth chromosome and involves excessive reduplication of the cytosine-adenine-guanine 
(CAG) base of deoxyribonucleic acid (DNA) (Gudesblatt & Tarsy, 2011). The length of 
CAG repeats  inversely  correlates  with  age  of  onset  (Gudesblatt  &  Tarsy,  2011)  and 
manifestation of HD typically occurs with CAG repeats of 36 or more. This mutation 
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impedes the proper function of the gene, leading to eventual degeneration of grey matter 
in  the  basal  ganglia,  left  striatum,  and  prefrontal  cortex,  areas  which  control  motor 
function,  language,  and  cognition  (respectively)  (Lambrecq,  2013;  Azambuja  et  al., 
2012).
Degeneration in these areas results in a variety of symptoms in HD, including 
chorea;  dystonia,  defined  as  a  movement  disorder  that  causes  involuntary  muscle 
contracture; dysphagia, defined as a dysfunction of the oral cavity, pharynx, esophagus, 
or gastroesophageal junction during swallowing; muscle rigidity; difficulty executing fine 
motor movements; trouble producing speech; cognitive deficits; changes in personality or 
behavior  (depression,  suicidal  thoughts);  and  hallucinations  (Mayo  Foundation  for 
Medical  Education  and  Research,  2017;  American-Speech-Language-Hearing 
Association  [ASHA],  2017;  Roos,  2010).  These  symptoms often  characterize  distinct 
stages of the disease and change with progression.
More specifically, the course of HD can be divided into three stages: preclinical 
stage, transition stage, and clinical stage. The preclinical stage can be further divided into 
the at-risk stage and pre-manifest stage. The at-risk stage begins when at least one parent 
is affected by HD, leading to the child’s uncertainty of carriership (Roos, 2010). The at-
risk stage ends and the pre-manifest stage begins once it is determined that the child is a 
carrier (Roos, 2010). During the transition phase, the carrier may develop strong feelings 
about changes in behavior, movement, and cognition while uncertainty remains (Roos, 
2010).  Finally,  the  clinical  stage  can  be  further  divided  into  three  sub-stages. 
Neurological, cognitive, and psychiatric symptoms are often the first symptoms of HD 
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and are observed in the first clinical stage (Roos, 2010). Chorea is the most prominent 
symptom in this stage; however, activities of daily living remain relatively independent 
(Roos, 2010). Motor symptoms become more generalized in the second clinical stage and 
death by suicide may occur (Roos, 2010). During the third and final clinical stage, chorea 
becomes severe, leading to complete physical dependence on family and eventual death 
(Roos, 2010). Additionally, although research has long documented the dysfunction and 
progressive deterioration of speech, language, and swallow in HD, it is unclear how they 
evolve in relation to these clinical stages. In summation, HD is characterized by a wide 
variety  of  symptoms,  including  movement,  behavioral,  cognitive,  and  linguistic 
disturbances, which vary in prominence over the course of the disease (Gudesblatt  & 
Tarsy, 2011). Currently, there is no known cure or medication to help slow progression of 
the disease. As such, SLPs play a role in the management of HD and its symptomatology, 
with  the  goal  of  minimizing  complications  and  maximizing  quality  of  life  for  those 
affected (Gudesblatt & Tarsy, 2011). 
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Chapter 2:  Diagnosis
In keeping with ethical guidelines, the SLP should always refer the patient to an 
appropriate licensed medical professional for proper medical examination and diagnosis 
when HD is suspected,  but not otherwise clinically diagnosed.  Generally,  a definitive 
diagnosis  of  HD  can  be  obtained  through  genetic  testing.  Motor,  psychiatric,  and 
cognitive evaluations as well as brain imaging (MRI) can also aid in the diagnosis of HD 
(Roos, 2010). Standardized tests such as the Unified Huntington Disease Rating Scale 
and  Problem Behaviour  Scale,  as  well  as  other  measures,  can  also  be  used  to  scale 
symptomatology,  behavior,  and  perceived  impact  of  the  disease  on  quality  of  life 
(Huntington Study Group [HSG], 2015; Craufurd, Thompson, & Snowden, 2001; Roos, 
2010).  Such  diagnostic  tools  exemplify  the  progress  made  in  understanding  HD. 
Nonetheless,  along  with  these  advancements,  it  is  also  important  to  consider  that 
receiving an official diagnosis may have ethical, medical, and emotional consequences on 
the  patient  and  their  family  (Andersson,  Juth,  Petersén,  Graff,  &  Edberg,  2013). 
Ultimately, the patient may choose to not receive an official diagnosis (Andersson et al., 
2013).
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Chapter 3:  Description and Management of Specific Symptomatology 
in HD
CHOREA
Neurodegeneration  of  the  basal  ganglia  due  to  HD  results  in  a  disorder  of 
movement known as chorea (Lamrecq et al., 2013). Chorea, characterized by random, 
involuntary, jerk-like muscle contractions that vary in frequency, amplitude, and intensity, 
is the most common clinical feature and often one of the first symptoms of HD (Foroud, 
Gray, Ivashina, & Conneally, 1999; Jankovic, 2009; Roos, 2010). The severity of chorea 
can range from facial  twitching to  contraction of  the  limbs  and trunk that  results  in 
disturbances in gait and balance (Jankovic & Roos, 2014). Emotional, psychological, and 
environmental stressors can influence the severity of the chorea (Jankovic & Roos, 2014). 
Even so, studies have shown that people with HD are often unaware of their choreatic 
symptoms until they begin to negatively impact their life, such as with job performance 
(Snowden, Craufurd, Griffiths, & Neary, 1998; Sitek et al., 2011). As a result, treatment 
of chorea in HD should begin by educating the patient and their family about his or her 
physical limitations (Jankovic & Roos, 2014). Furthermore, as chorea begins to hinder 
activities  of  daily living,  the patient  may choose to begin pharmacological  treatment. 
Currently, Tetrabenazine is one of only two medications approved by the United States 
Food and Drug Administration for treatment of chorea (U.S. FDA, 2017). At present, it is 
unclear  whether  this  drug’s  benefits  outweigh  its  adverse  effects,  which  can  include 
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sedation, insomnia, and depression (Killoran & Biglan, 2014; Jankovic & Roos, 2014). 
More recently,  the U.S.  FDA approved Deutetrabenazine for  the treatment of  chorea; 
however,  it  is  unclear how the drug compares to Tetrabenazine in regard to reducing 
chorea and its adverse effects (Frank et al., 2016; HSG, 2006; Geschwind & Paras, 2016; 
U.S. FDA, 2017). Nevertheless, the approval of this second pharmacological treatment 
for  chorea  is  evidence  of  the  progress  being  made  toward  better  understanding  and 
treatment of chorea in HD.
SPEECH AND LINGUISTIC/PARALINGUISTIC DEFICITS
Hyperkinetic dysarthria, a motor speech disorder usually resulting from damage 
to the basal ganglia, is common in those with HD and may disturb speech by affecting 
respiration,  phonation,  and  articulation  (McCaffrey,  2013).  Speech  may  also  become 
aprosodic, excessively loud, and harsh (Hartelius, Jonsson, Rickeberg, & Laakso, 2010). 
Patients with HD may demonstrate lower speech rates, an increase in number of pauses, 
and difficulty repeating single syllables  (Skodda,  Schlegel,  Hoffmann,  & Saft,  2014). 
Additionally, imprecise vowel articulation and excess intensity variations are also speech 
deficits  observed  in  people  with  the  disease  (Rusz  et  al.,  2014).  Furthermore, 
antidopaminergic medication, often used in the treatment of HD, can negatively impact 
speech by inducing excessive loudness and pitch variations and highlighting problems 
with  speech  timing  (Rusz  et  al.,  2014).  Overall,  dysarthria  and  the  side  effects  of 
medication may together negatively affect speech production in people with HD. 
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Even as research has consistently described the speech alterations in HD, few 
descriptions  exist  regarding  linguistic  disturbances  or  their  determinants  in  HD 
(Azambuja  et  al.,  2012).  Early  in  the  disease,  when  neural  degeneration  is  confined 
mainly  to  the  striatum,  deficits  in  impaired  lexical  retrieval  may be  observed in  HD 
(Azambuja et al., 2012). Later in the disease, degeneration of the frontal and temporal 
regions may further disturb language, but it is unclear what specific deficits may arise as a 
result (Azambuja et al., 2012). In general, linguistic alterations observed in people with 
HD may include poorer performance in verbal fluency, narrative writing, and oral and 
reading comprehension (Azambuja et al., 2012). Individuals with HD may present with 
difficulty  processing  metaphors,  inferences,  and  comprehending  implicit  information 
(Hartelius  et  al.,  2010).  These  deficits,  however,  may  reflect  difficulties  with  tasks 
involving complex material rather than frank aphasia (Azambuja et al., 2012).
In  addition  to  the  aforementioned  linguistic  alterations,  research  has  long 
documented  the  presence  of  paralinguistic  deficits,  including  problems  with  emotion 
recognition,  in  people  with  HD  (Henley  et.  al.,  2012;  Paulsen,  2011).  In  particular, 
processing  of  the  facial  expression  for  disgust  has  repeatedly  been  observed  to  be 
impaired in those with HD and can be attributed to the underlying dysfunction of neural 
systems  and  structures  involved  in  processing  of  disgust  (Aviezer  et  al.,  2009; 
Sprengelmeyer,  Schroeder,  Young,  &  Epplen,  2006).  More  recently,  research  has 
suggested  that  this  impairment  extends  to  the  recognition  of  all  negative  facial 
expressions in people with HD (Johnson et al., 2007). However, despite these deficits, 
studies have shown that patients with HD may be able to successfully identify facial 
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expressions when embedded in context, supporting the efficacy of training in this area to 
improve communication (Avizezer et al., 2009). Furthermore, given that such deficits are 
often seen early in the progression of the disease, emotion processing deficits have the 
potential to be used as an early biomarker (Paulson, 2011; Henley et. al., 2012). Overall, 
it is evident that SLPs must first understand the intricacies and progression of speech and 
linguistic/paralinguistic deficits throughout the course of HD for proper treatment.
Unfortunately,  to  the  author’s  knowledge,  there  are  currently  no  studies  that 
describe the efficacy of speech-language therapy for the management of such deficits or 
preservation of communicative function in HD. In part, this lack of evidence may result 
from the difficulty in disambiguating speech and language deficits from cognitive deficits. 
It  may also be attributed to the level of attention placed on what are perceived to be 
greater  health  risks,  such  as  chorea,  behavior,  and  dysphagia,  which  arise  from HD. 
Nevertheless, this current gap in the literature highlights the strong need for studies to 
examine the efficacy of speech-language therapy for the preservation of language in HD. 
Future directions for such studies may investigate the efficacy of traditional intervention 
approaches  for  speech  and   language  in  the  preservation  of  such  functions  and  the 
resultant impact on quality of life in people with HD. In the absence of such evidence, 
from a clinical expertise standpoint, linguistic management in HD may heavily rely on 
encouraging the patient to use compensatory strategies for communication. 
Compensatory strategies for the speaker can include speaking more slowly, saying 
one word at a time, repeating/rephrasing, over-articulating, keeping sentences short, and 
using  gestures  (ASHA,  2017).  Therapy  should  also  target  teaching  the  primary 
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communication  partner  strategies  regarding  how  to  make  personal  adjustments  to 
facilitate  effective  communication.  Some  examples  of  personal  adjustments  include 
allowing turn-taking during conversation, slowing their own rate of speech, repeating/
reiterating, keeping questions/statements simple, asking one question at a time, using a 
yes/no question format, asking for clarification or repeating what you think was said in 
the form of a question, and eliminating distractions (ASHA, 2017). 
With advancement of the disease, augmentative and alternative communication 
(AAC), defined as communication conveyed by any means except verbal output, may 
help the patient with HD to express themselves (ASHA, 2017). AAC can be unaided, 
relying on body language and gestures to facilitate or enhance communication (ASHA, 
2017).  Aided  forms  of  AAC  can  range  from  low-tech  (e.g.,  paper  and  pencil, 
communication  boards)  to  hi-tech  (e.g.,  speech  generating  devices  which  can  be 
programmed to create messages) (ASHA, 2017). Furthermore, some research has proven 
such  AAC  devices  effective  in  facilitating  communication  in  those  with  HD  (e.g., 
Gelsvartas, Simutis, & Maskeliunas, 2016). Overall,  in the absence of evidence-based 
speech  and  language  interventions  for  people  with  HD,  the  use  of  compensatory 
strategies as well as AAC may help enhance and facilitate communication.
Furthermore, in order to fulfill our duties in improving communication in people 
with HD, SLPs must understand the psychosocial issues surrounding the disease. Some 
research  has  indicated  that  patients  with  HD  may  perceive  a  negative  impact  on 
communication when their communication partners speak too fast (Hartelius et al., 2010). 
Conversely, family members and caregivers may stress a lack of conversational depth, 
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perceived personality changes in their loved one, and lack of eye contact as factors that 
negatively  impact  communication  (Hartelius  et  al.,  2010).  Given  the  disagreement 
between the perceived factors negatively impacting communication, it is evident that both 
the  patient  and their  communication partners  may benefit  from engaging in  clinician 
mediated open dialogue to discuss such issues. Moreover, given that both the patients 
with HD and their communication partners identified a need for increased communication 
opportunities,  the  SLP  should  not  only  help  bridge  the  aforementioned  perceived 
differences,  but  also  help  families  identify  opportunities  to  engage  in  qualitative 
communication  (Hartelius  et  al.,  2010).  In  summary,  SLPs  must  first  understand  the 
psychosocial issues surrounding patients with HD and their families as well as our role in 
counseling to ensure continuity of care and help improve communication in people with 
HD.
Behavior and Cognition
Behavioral dysfunction is typically one of the first symptoms in HD. Irritability is 
often the first sign of psychiatric dysfunction; however, depression, anxiety, aggression, 
obsessions/compulsions, and hallucinations are also behavioral disturbances observed in 
HD  (Roos,  2010).  Additionally,  suicidal  ideation  is  common  in  patients  with  HD 
(Craufurd, Thompson, & Snowden, 2001). In fact, suicide is a leading cause of death 
among people with HD, with higher rates than for any other neurodegenerative disease 
(Halpin, 2012, Arciniegas & Anderson, 2002; Paulsen, Hoth, Nehl, & Stierman, 2005). If 
the SLP suspects that the patient is presenting with any psychological problems, he or she 
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may need to refer the patient to his or her doctor for further referral to an appropriate 
licensed mental health specialist. Furthermore, when working with a patient with HD, the 
SLP should consider the effects that both behavioral as well as cognitive disturbances 
may have on motivation and ability to participate.
Cognitive  decline  is  one  of  the  more  common  symptoms  of  HD  and  often 
precedes  observable  motor  dysfunction  (Stout  et  al.,  2011;  Roos,  2010).  Cognitive 
symptoms in HD result primarily from dysfunction of the basal ganglia, with deficits in 
attention,  working  memory,  and  executive  function  (Azambuja  et  al.,  2012).  With 
progression  of  the  disease,  frontal  and  temporal  regions  involved  in  visuospatial 
processing and episodic memory may be affected (Azambuja et al., 2012). In general, 
speed of cognitive processing may be slowed even in the early stages of HD and simple 
mental tasks may become more tiring and effortful (Paulsen, 2011). Although individuals 
with the disease may have difficulty with explicit learning and memory, they may display 
even  greater  difficulty  with  tasks  requiring  implicit  memory,  such  as  driving  a  car, 
playing a musical instrument, and even swallowing (Paulsen, 2011). Patients with HD 
may  also  demonstrate  impairment  in  estimation  of  time  that  can  precede  deficits  in 
movement by up to 15 years. Moreover, research has suggested that such deficiencies in 
behavior  and  cognition  in  patients  with  HD may  place  the  greatest  burden  on  their 
families and are highly associated with functional decline and likelihood of nursing home 
placement (Hamilton et al., 2003; Nehl and Paulsen, 2004; Williams et. al., 2010). In the 
absence  of  evidence-based  treatment  approaches  for  HD-related  cognitive  decline, 
treatment should focus on maximizing functionality and quality of life.
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Furthermore, in order to help improve the quality of life of patients with HD and 
their families, SLPs must understand our full role in providing support services. Some 
studies  have  indicated  that  health  and  personal  care  and  social  support  services  are 
primary unmet needs among patients with HD (van Walsem, Howe, Iversen, Frich, & 
Andelic, 2014). These findings accentuate the need for SLPs to take a more active role in 
facilitating  support  services  and  identifying  resources  for  HD families.  Support  may 
involve  locating  and  informing  HD  families  regarding  HD-specific  support  groups. 
Locating resources for home-health support may also be beneficial.  In summary, it  is 
critical that SLPs take an active role in providing support and resources to help improve 
quality of life for those affected by HD.
SWALLOW
Through  progression  of  HD,  swallowing  may  become  problematic,  posing  a 
choking hazard as symptoms of both dysarthria and dysphagia become prominent (Roos, 
2010).  Motor  weakness  and incoordination  can  affect  the  function  of  the  pharyngeal 
muscles, heightening the risk of aspiration. General symptoms of dysphagia may include 
spillage  of  food,  drooling,  difficulty  chewing,  coughing,  and  lip/tongue  weakness 
(Dalton, Caples, and Marsh, 2011). Some studies have found that, in people with HD, 
most dysphagia symptoms occurred in the in the preparatory, oral, and pharyngeal phases 
of swallow and included postural instability, rapid and impulsive consumption of food, 
and poor lingual control (Heemskerk and Roos, 2011). For these patients, the oral phase 
is often characterized by uncoordinated swallow, repetitive swallow, and post-swallow 
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residue (Heemskerk and Roos, 2011). Coughing, choking, and aspiration are often seen in 
the pharyngeal phase (Heemskerk and Roos, 2011). As is evidenced by the variety of 
dysfunction that can result from dysphagia, assessment of the different phases of swallow 
is critical, as these symptoms can be life-threatening. 
Given  that  dysphagia  is  a  leading  cause  of  aspiration,  pneumonia,  and 
asphyxiation, improper management of dysphagia can lead to a respiratory infection and 
even death (Dalton et al., 2011; Pritchard & Jones, 2014). A modified barium swallow 
will  yield  a  clear  picture  of  the  oral  and  pharyngeal  mechanisms during  swallowing 
(Dalton  et  al.,  2011).  Additionally,  some  researchers  have  identified  the  need  for  a 
validated dysphagia assessment scale specifically for HD-induced dysphagia in order to 
provide insight into the clinical features of the swallow observed throughout the course of 
the disease (Heemskerk and Roos, 2011). The Huntington's Disease Dysphagia Scale, is 
an 11-point severity scale for dysphagia (Heemskerk et al.,  2014). Although currently 
only validated in Dutch, the scale has been proven to exhibit high reproducibility and 
construct validity scores (Heemskerk et al., 2014). Overall, current assessment methods 
effectively  provide  a  clinical  description  of  the  swallow  impairment,  crucial  for 
appropriate treatment.
In  general,  dysphagia  management  may  consist  of  compensatory  strategies, 
including modifications in food and liquid consistency. Environmental modifications for 
dysphagia  management  may  include  informing  the  patient  or  caregiver  about  food 
presentation, special utensils and positioning of the patient (Dalton et al., 2011). In regard 
to  HD-specific  dysphagia  management,  some  research  has  proven  that  controlling 
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consistency and portion-size as well as implementing swallow patterns, such as chew-
swallow-cough-swallow, may reduce the frequency of penetration and aspiration, for as 
long as three years for some patients with HD (Kagel and Leopold, 1992). Other research 
has investigated the use of more specific approaches to address some of the dysphagia 
symptoms seen in people with HD. For instance, some studies have shown that placing a 
lemon  ice  bolus  on  the  patient’s  tongue  before  presentation  of  food  of  varying 
consistencies may help stimulate and slow oropharyngeal movements in people with HD 
(Kagel and Leopold, 1992). Nevertheless, what research has failed to prove is the efficacy 
of strengthening exercises for the improvement of swallow in HD (Adams, 2009).  In 
brief, a variety of compensatory strategies exist that have been proven effective for the 
management of HD specific dysphagia. Despite this, with advancement of the swallow 
dysfunction in people with HD, placement of a gastrostomy tube or feeding tube may be 
indicated as the individual loses total control of swallow function.
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Chapter 4:  Conclusion
This  paper  examined the available  research regarding the management  of  HD 
from a  CSD perspective  for  use  by  clinical  SLPs.  Our  current  understanding  of  the 
disease itself  has clearly burgeoned since its  first  description to the general  public in 
1872.  Specifically,  research  has  identified  and  characterized  phases  of  the  disease  to 
better describe its course and progression. Undoubtedly, this has paved the way for the 
development of current treatment options for those affected by the disease. The recent 
approval of a second U.S. FDA-approved drug is evidence of the progress being made 
toward better  understanding and treatment  of  chorea  in  HD.  Additionally,  other  non-
pharmacological  developments  have  resulted  in  a  deeper  understanding of  the  neural 
structures  implicated  in  HD  and  their  respective  disturbances.  Moreover,  the  above 
studies  have  documented  and  described  the  variety  of  disorders  involving  speech, 
language, cognition, and swallow affected in HD— areas which are well within the SLP’s 
scope of practice. Nonetheless, despite these advancements, evidence provided by this 
review  highlights  the  lack  of  research  examining  the  efficacy  of  speech-language-
cognitive-swallow rehabilitation  in  the  management  of  HD.  In  conclusion,  there  is  a 
strong  need  for  studies  that  investigate  the  effects  of  traditional  or  novel  speech-
language-cognitive and swallowing treatment approaches on the preservation of  these 
abilities in HD. Furthermore, SLPs must understand the psychosocial issues surrounding 
patients with HD and their families as well as our role in counseling and support services 
to ensure continuity of care and help improve quality of life. 
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